Brief: Argent Biopharma Files Provisional US Patent On Immune Modulation And Longevity
12/10/2026 02:37
BRIEF-Argent Biopharma Files Provisional US Patent On Immune Modulation And Longevity Oct 12 (Reuters) - Argent BioPharma Ltd RGT.AX:
STRATEGIC FOCUS ON IMMUNE MODULATION AND LONGEVITY
SECURES LICENSED COMMERCIALISATION RIGHTS TO NLC PORTFOLIO
FILES US PROVISIONAL PATENT APPLICATION NO. 63/979,136 FOR NANOBODY CONSTRUCTS
Further company coverage: RGT.AX
((Reuters.Briefs@thomsonreuters.com))
Recent news on Argent BioPharma
See all newsBrief: Argent Biopharma Executes Global Licence For Non-Core Cannabis Genetics
Brief: Argent Biopharma Files Provisional US Patent On Immune Modulation And Longevity
Australia's Argent BioPharma rises to over 1-month high on new licence agreement
Brief: Argent Biopharma Signs NLC Licence To Expand Antiviral Portfolio
Brief: Argent Biopharma Says FDA-CVM Established Inad File For Cannepil Veterinary Program